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Abstract
Background: Bone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or
reduced osteoblast bone formation, and is commonly associated with skeletal complications. Thus, there is a need to
identify new agents capable of influencing bone remodeling. We aimed to further pre-clinically evaluate the effects of
dasatinib (BMS-354825), a multitargeted tyrosine kinase inhibitor, on osteoblast and osteoclast differentiation and function.
Methods: For studies on osteoblasts, primary human bone marrow mensenchymal stem cells (hMSCs) together with the
hMSC-TERT and the MG-63 cell lines were employed. Osteoclasts were generated from peripheral blood mononuclear cells
(PBMC) of healthy volunteers. Skeletally-immature CD1 mice were used in the in vivo model.
Results: Dasatinib inhibited the platelet derived growth factor receptor-b (PDGFR-b), c-Src and c-Kit phosphorylation in
hMSC-TERT and MG-63 cell lines, which was associated with decreased cell proliferation and activation of canonical Wnt
signaling. Treatment of MSCs from healthy donors, but also from multiple myeloma patients with low doses of dasatinib (2–
5 nM), promoted its osteogenic differentiation and matrix mineralization. The bone anabolic effect of dasatinib was also
observed in vivo by targeting endogenous osteoprogenitors, as assessed by elevated serum levels of bone formation
markers, and increased trabecular microarchitecture and number of osteoblast-like cells. By in vitro exposure of hemopoietic
progenitors to a similar range of dasatinib concentrations (1–2 nM), novel biological sequelae relative to inhibition of
osteoclast formation and resorptive function were identified, including F-actin ring disruption, reduced levels of c-Fos and
of nuclear factor of activated T cells 1 (NFATc1) in the nucleus, together with lowered cathepsin K, aVb3 integrin and CCR1
expression.
Conclusions: Low dasatinib concentrations show convergent bone anabolic and reduced bone resorption effects, which
suggests its potential use for the treatment of bone diseases such as osteoporosis, osteolytic bone metastasis and myeloma
bone disease.
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Introduction
Bone mass is regulated by the balance of bone formation and
bone resorptive rates. Alteration of this balance by increased
number and activity of bone-resorbing osteoclasts (OCs) and/or
reduced differentiation and impaired activity of bone-forming
osteoblasts (OBs), leads to pathological states of bone loss. That is
the case of bone diseases such as osteoporosis, osteolytic bone
metastasis and multiple myeloma bone disease. In osteoporosis, a
prevalent disease of postmenopausal women and elderly patients,
bone resorption exceeds that of bone formation resulting in a
systemic impairment of bone mass, strength, and microarchitec-
ture [1]. This highly increases the propensity of fragility fractures,
most commonly occurring in the spine, hip or wrist. Also, many
solid tumors (prostate, breast, lung, colon, renal), commonly
metastasize to bone. When this occurs, tumor cells mobilize
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promote bone invasion and enhance tumor growth, which leads to
deregulated bone remodeling and as a consequence, devastating
skeletal complications [2,3]. Furthermore, multiple myeloma
(MM) is a hematological malignancy primarily developing within
the bone marrow as a consequence of the abnormal expansion of
clonal plasma cells. Interestingly, one major (in up to 80% of MM
patients) clinical symptom associated with this disease is the
development of osteolytic lesions as a result of increased bone
resorption and marked impairment of bone formation. The
interactions of myelomatous cells with the bone marrow
microenvironment are thought to be critical in the development
of MM bone disease, and the diverse interplaying cellular and
molecular components have been extensively studied recently [4–
6]. Of interest, isolated mesenchymal osteoprogenitor cells from
the bone marrow of myeloma patients have been reported to show
distinct gene expression profile and also reduced osteogenic
potential as compared to those from healthy donors [7,8]. All these
low bone mass pathologies (osteoporosis, osteolytic bone metastasis
and myeloma bone disease) cause skeletal fragility and are
commonly associated to skeletal related events including patho-
logical fractures, severe bone pain, hypercalcemia and spinal cord
and nerve compression. These events can severely compromise the
quality of life of patients and even result in significant mobidity
and increased risk of death. This emphasizes the need to identify
and develop new bone-targeted pharmacological agents which
may prevent, reduce or even reverse these pathological conditions
of bone loss in the above mentioned diseases.
Specific tyrosine kinases have been proposed as potential targets
for anti-tumor therapy. Imatinib mesylate (STI-571) is a tyrosine
kinase inhibitor which was originally approved as a first-line
treatment for chronic myeloid leukemia because of its capacity to
inhibit the Bcr-Abl kinase activity of Philadelphia
+ cells [9].
Additional tyrosine kinases with oncogenic potential also inhibited
by imatinib include c-Kit, the platelet-derived growth factor
receptors: PDGFR-a and PDGFR-b, and the c-Fms receptor
[9,10], which account for the anti-tumor effect of imatinib in
several types of solid tumors. Interestingly, evidence has
accumulated for a direct effect of imatinib in the skeleton with
increased trabecular bone volume and bone mineral density in
imatinib-treated patients [11,12]. In vitro studies showed that
imatinib suppressed OB proliferation and stimulated osteogenic
gene expression and mineralization majorly by inhibiting PDGFR
function [11,13]. Moreover, imatinib has a potent inhibitory effect
on OC bone resorption and stimulates apoptosis of mature OCs
[14].
Dasatinib (BMS-354825) is a novel oral bioactive multitargeted
tyrosine kinase inhibitor which was developed as a second-
generation drug rationally designed for the use against imatinib-
resistant leukemias [15]. The target tyrosine kinase profile of
dasatinib partially overlaps that of imatinib but presenting much
higher potency, and is also broader, including the Src family
kinases [10]. Dasatinib is now being evaluated in Phase II trials in
a variety of tumor types, including prostate, breast, colorectal and
lung cancer [16]. However, taking into account the aforemen-
tioned skeletal effects of imatinib, it was expected that dasatinib
might be even more effective in inhibiting osteoclastogenesis and
promoting bone formation. In fact, it has already been reported
that dasatinib inhibits OC formation and resorption capacity,
mainly by its potent inhibition of c-Fms on OC progenitors
[17,18]. Also, recent data of dasatinib effect enhancing osteo-
blastogenesis from mesenchymal progenitors have been reported
[19-21]; other authors, however, have claimed an inhibitory effect
on OB differentiation for this agent in similar settings [22]. In the
present study we provide in vitro evidences of the effect of low
dasatinib concentrations in enhancing differentiation and function
of mesenchymal osteoprogenitors from both healthy donors, and
interestingly, also from myeloma patients. This anabolic bone
effect of dasatinib was also observed in the in vivo setting after
administration of relatively low dasatinib doses to skeletally-
immature mice to avoid the inhibitory effects of the agent on OCs
and OC precursors and thus targeting endogenous osteoprogeni-
tor cells. Besides, within the same low nanomolar range of
dasatinib concentrations, we show in vitro data of additional
mechanisms of dasatinib inhibitory effect on OC differentiation
[diminished expression of c-Fos and reduced levels of nuclear
factor of activated T cells 1 (NFATc1) in the nuclear compart-
ment], and on OC function (F-actin ring disruption and lowered
aVb3 integrin, CCR1 and cathepsin K expression). Taken
together, our data support the overall bone anabolic effects of
dasatinib, with a double component of enhancement of OB
differentiation and function together with inhibition of osteoclas-
togenesis and bone resorption, exerted within a similar concen-
tration range. Potential therapeutic implications of dasatinib for
the treatment of specific bone disorders are also discussed.
Methods
Participants
Samples from the bone marrow of 10 healthy donors and 10
newly diagnosed MM patients (stages I to III) were used in this
study after informed and written consent of participants. Approval
of the study was granted by the Institutional Review Board of the
CIC, IBMCC (University of Salamanca-CSIC, Spain), and
research was conducted following principles in the Declaration
of Helsinki.
Reagents and immunochemicals
Dasatinib was provided by Bristol-Myers Squibb Company
(Stamford, CT, USA). For in vitro assays, dasatinib was
reconstituted in dimethyl sulfoxide (DMSO; Merck, Hohenbrunn,
Germany) at a stock concentration of 100 mM and stored at
220uC; further dilutions were made in tissue culture medium at
the time of use. Recombinant human PDGF-BB, macrophage
colony-stimulating factor (M-CSF) and receptor activator of NF-
kB ligand (RANKL) were purchased from Peprotech (London,
UK), while stem cell factor (SCF) was obtained from Strathmann
(Hamburg, Germany). Primary antibodies for immunoblotting,
immunohistochemical and flow cytometry analyses were directed
against: PDGFR-b, phospho-PDGFR-b (Tyr857), Erk1/2, phos-
pho-Erk1/2 (Thr202/Tyr204), NFATc1, histone H1 and cathep-
sin K, purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); phospho-c-Fms (Tyr723), phospho-c-Kit (Tyr719), c-
Src, phospho-Src (Tyr416), p38 MAPK, phospho-p38 MAPK
(Thr180/Tyr182), Akt, phospho-Akt (Ser473), phospho-b-catenin
(Thr41/Ser45), PU.1 and c-Fos, from Cell Signaling Technology
(Danvers, MA, USA); CD51/61 and CD191, from R&D Systems
(Minneapolis, MN, USA); c-Kit and nucleoporin p62, from BD
Biosciences (Bedford, MA, USA); a-tubulin, from Calbiochem
(Darmstadt, Germany); dephospho-b-catenin (aa 35–50), from
Enzo Life Sciences (Plymouth Meeting, PA, USA), and T-cell
factor 4 (Tcf4), from Upstate (Millipore, Billerica, MA, USA). All
cell culture media and reagents were purchased from Gibco
(Paisley, UK). Trypan Blue Solution 0.4% was delivered by
Sigma-Aldrich (St. Louis, MO, USA), and the alamarBlue reagent
by Invitrogen (Carlsbad, CA, USA).
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The human mesenchymal stem cell (MSC) line immortalized by
expression of the telomerase reverse transcriptase gene (hMSC-
TERT) was a generous gift from Dr D Campana (Department of
Oncology and Pathology, St Jude Children’s Research Hospital,
Memphis, TN, USA) [23]. The human osteosarcoma cell line
MG-63 was obtained from the American Type Culture Collection
(CRL-1427; LGC Promochem, London, UK), and used as an
osteoblast-like cell line [24]. Cell lines were grown in RPMI 1640
medium (hMSC-TERT) or DMEM medium (MG-63) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
100 U/mL penicillin and 100 mg/mL streptomycin. All cell types
were cultured at 37uC in a humidified atmosphere in the presence
of 5% CO2–95% air.
Primary mesenchymal stem cells and osteoprogenitor
cells
Primary MSCs from BM samples of healthy donors (n=10) and
MM patients (n=10) were generated as described by Garayoa et
al. [25]. Briefly, mononuclear cells from bone marrow samples
were isolated using Ficoll-Paque density gradient centrifugation (r
1.073; GE Healthcare, Uppsala, Sweden), cultured in DMEM
with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin
and 2 mM L-glutamine for four days and selected by their
adherence to plasticware. The culture medium was replaced twice
weekly until MSC cultures were approximately 90% confluent or
had been in culture for a maximum of 21 days; at that point, cells
were trypsinized (0.05% Trypsin-EDTA) and expanded in a 1:3
ratio. At passage 3, selected MSCs from both origins were tested to
meet definition criteria according to the recommendations of the
International Society for Cellular Therapy [26] and experiments
were performed.
To induce ex vivo differentiation to OBs, the growth medium of
MSCs at 80–90% confluence was replaced by an osteogenic
differentiation medium consisting of a-MEM supplemented with
10% FBS, 10 mM b-glycerol phosphate, 50 mg/mL ascorbic acid
and 10 nM dexamethasone (all additives from Sigma-Aldrich).
MSCs were grown in the osteogenic medium for 7 (early stage of
OB differentiation), 14 (pre-OB stage) or 21 days (fully differen-
tiated OBs), replacing the medium every 3 or 4 days, in the
absence or presence of specified concentrations of dasatinib.
Cell proliferation and viability assays
To test whether dasatinib affected the growth capacity of the
MSC/OB lineage, the hMSC-TERT and MG-63 cell lines were
seeded in 6-well plates at 10
4 cells/cm
2 or 2.5610
3 cells/cm
2,
respectively, and incubated for 7 days in the absence or presence
of different dasatinib concentrations. Cells were then trypsinized
(0.05% Trypsin-EDTA) and counted using a Trypan Blue solution
and a haemocytometer. The alamarBlue reagent was used to
examine cell viability of the hMSC-TERT and primary MSCs
from myeloma patients at different time points and dasatinib
concentrations along the osteogenic differentiation process, as by
manufacturers instructions.
In addition, to check whether changes in the number of viable
cells were due to diminished proliferative capacity or apoptotic
effects of the drug, the hMSC-TERT cell line was stained with
PKH67 (Sigma-Aldrich), a green fluorescent cell tracker that is
retained in the cell membrane and thus can be used for monitoring
proliferation based on dye dilution with each cell division. After
PKH67 labeling, cells were seeded in 6-well plates at 10
4 cells/cm
2
and incubated for 7 days in the osteogenic differentiation medium
in the presence or absence of dasatinib. At the end of the culture
period, cells were trypsinized and incubated with phycoerythrin
(PE) conjugated Annexin-V and 7-amino-actinomycin D (7-AAD)
[Becton Dickinson (BD) Biosciences, Bedford, MA, USA] for
complementary apoptosis/necrosis information. The cells were
acquired using a FACSCalibur flow cytometer, and data were
analyzed using the ModFit program to determine the number of
cell divisions and the percentage of cells in each division
(compared with undivided colcemid-treated cultures) or the
Paint-A-Gate program for percentages of apoptotic cells (BD
Biosciences).
Western blotting analyses
Protein lysates were generated and western blotting procedures
were performed as previously described [27]. For subcellular
fractionation of proteomic samples, the Qproteome Cell Com-
partment kit was used (Qiagen GmbH, Hilden, Germany).
Detection of PDGFR-b, phospho-PDGFR-b (Tyr857), c-Kit,
phospho-c-Kit (Tyr719), c-Src, phospho-Src (Tyr416), Erk1/2,
phospho-Erk1/2 (Thr202/Tyr204), p38 MAPK, phospho-p38
MAPK (Thr180/Tyr182), Akt, phospho-Akt (Ser473), phospho-c-
Fms (Tyr723), PU.1, NFATc1, c-Fos, cathepsin K, phospho-b-
catenin (Thr41/Ser45), dephospho-b-catenin (aa 35–50), histone
H1 and a-tubulin was performed by a standard procedure, using
primary and appropriate horseradish peroxidase-conjugated
secondary antibodies and a luminol detection system with p-
iodophenol enhancement for chemiluminescence.
To analyze the effect of dasatinib on PDGFR-b, c-Kit and c-Src
tyrosine kinases, the hMSC-TERT and MG-63 cell lines were first
incubated with different concentrations of dasatinib for 6 hours
and then treated with 10 ng/mL PDGF-BB or 50 nM SCF for
20 minutes prior to protein isolation. To test the effect of dasatinib
on c-Fms, c-Kit and c-Src, OC progenitors were incubated with
dasatinib for 2 hours and then treated with 50 ng/mL M-CSF or
50 nM SCF for 20 minutes prior to protein isolation.
Alkaline phosphatase and Runx2 activities and
mineralization assay
Primary MSCs were cultured in 12-well plates in MSC medium
until reaching ,80% confluency. Cells were then changed to the
osteogenic differentiation medium in the presence or absence of
dasatinib (2 or 5 nM) for 7 or 21 days, at which times the alkaline
phosphatase (ALP) activity, or the Runx2 activity and minerali-
zation assays were performed.
To measure ALP activity, cells were washed in phosphate-
buffered saline (PBS), lysed in ice-cold lysis buffer and protein
content determined using the Micro BCA assay kit (Pierce,
Rockford, IL). ALP activity was determined by specific hydrolysis
of p-nitrophenylphosphate into p-nitrophenol (Sigma-Aldrich) and
quantified by OD reading at 405 nm in triplicate using a
microplate reader (Asys UVM340, Biochrom, Eugendorf, Austria).
Values were referred to the total protein content of the sample.
When determining Runx2 activity, protein nuclear extracts
were prepared using the Qproteome Cell Compartment kit.
Quantification of Runx2 activation was performed with the
ELISA based Trans-AM (AML-3/Runx2) kit as per manufacturer
instructions.
For quantitative analysis of alizarin red staining (ARS), we used
the method described by Gregory et al. [28]. Briefly, cells were
fixed with 10% ice-cold phosphate-buffered formaldehyde for
10 minutes, rinsed with distilled water and stained with 40 mM
alizarin red (pH 4.2) for 20 minutes at room temperature. After
several washes to reduce non-specific ARS, stained cultures were
photographed with an Olympus DP70 camera on an Olympus 31
inverted microscope. Dye was extracted by acetic acid incubation
Bone Effects of Dasatinib
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well plates.
Real-time RT-PCR analysis
To evaluate the effect of dasatinib on the expression of bone
formation markers throughout their osteogenic differentiation,
MSCs from MM patients or healthy donors were cultured for 7 or
14 days in the osteogenic differentiation medium in the presence or
absence of the drug. Total RNA was isolated using the Rneasy Mini
kit (Qiagen GmbH, Hilden, Germany). Reverse transcription was
performed with 1.0 mg RNA in the presence of random hexamers
and 100 U of SuperScript RNase H reverse transcriptase (Invitro-
gen). For PCR reactions we used the Step One Plus Real-Time PCR
System and TaqMan Gene Expression Assays (Applied Biosystems,
Foster City, CA, USA) according to manufacturer’s instructions.
Assay IDs were: ALP, Hs00758162_m1; COL1A1, Hs01076777_m1,
Osterix, Hs00541729_m1, and Runx2, Hs01047976_m1. Experi-
ments were performed in duplicate for both the target and the
endogenous gene (GAPDH) used for normalization. Relative
quantification of the target gene expression was calculated by the
comparative threshold cycle (Ct) method: 2
–DDCt where DCt=
Ct target gene –C tGAPDH and DDCt=DCt dasatinib-treated samples –
DCt samples in absence of dasatinib.
In vivo model
For in vivo studies, dasatinib powder was dissolved in sterile
80 mM citric acid pH 2.1 to make a 10 mg/mL stock solution and
then further dilutions were made in 80 mM sodium citrate
pH 3.1. Thirty 5-week-old female CD1 healthy mice were housed
at our Animal Care Facility. At this age, healthy CD1 mice are
skeletally immature and show very active bone formation and
minimal bone resorption, and this model was chosen so that the
effect of dasatinib on bone could be majorly ascribed to its action
on OBs and not to inhibition of OC formation and function.
Animals were divided into three groups (n=10 in each group)
receiving: a) 80 mM sodium citrate pH 3.1 as vehicle; b) a lower
dasatinib dose of 2.5 mg/kg, and c) a higher dasatinib dose of
10 mg/kg. Treatment was administered by oral gavage in
0.01 mL volume, in a BID regimen (twice a day), 5 days/week
in an attempt to maintain the dasatinib concentration range
throughout the day. Serum samples were collected at the
beginning of the experiment, and also after 3 and 7 weeks of
dasatinib treatment (n=7 per group). Three to 5 animals per
group were sacrificed after 3 and 7 weeks of treatment, and both
femurs were dissected for microtomographic imaging (micro-CT),
histological and immunohistochemical analyses. All animal
experiments were conducted according to Institutional Guidelines
for the Use of Laboratory Animals of the University of Salamanca,
after acquiring permission from the local Ethical Committee for
Animal Experimentation, and in accordance with current Spanish
laws on animal experimentation.
Osteocalcin and ALP (as markers of new bone formation) as
well as TRAP5b levels (the active isoform of TRAP, specifically
expressed by OCs, and thus reflecting OC number and activity),
were quantified in collected sera. Markers of bone metabolism
were measured by dedicated ELISAs according to manufacturers
guidelines [Alkaline phosphatase (Sigma-Aldrich), Mouse osteo-
calcin (Biomedical Technologies, Stoughton, MA, USA) and
Mouse TRAP Assay (Immunodiagnostic Systems, Boldon, UK)].
For statistical analysis, values for a determined serum marker (e. g.
osteocalcin) at each point (control, 3 and 7 weeks of treatment)
were normalized for every individual animal to its own osteocalcin
level at the beginning of the experiment, and plotted as fold
change.
To assess bone morphology and microarchitecture, 10%
formalin-fixed femurs were analyzed by a micro-CT system
(MicroCATII; Siemens, Knoxville, TN, USA) at 75.0 kVp and
250.0 uA. Seven hundred X Ray projections were acquired during
a 200u rotation around the sample, with 1250 ms camera exposure
time per projection at full resolution (5126512). The reconstruc-
tion of the 3D image was done using COBRA V6.1.8 (Exxim
Computing Corporation, Pleasanton, CA, USA) with a final
resolution of 10.4 mm/voxel. The post-processing, rendering and
generation of the cross sections of the samples was done using
Amira (Visage Imaging, San Diego, CA, USA). Analysis of
microarchitectural trabecular bone morphology in the distal femur
was performed using CT-Analyser software (SkyScan, Kontich,
Belgium). Quantitative bone determined parameters were the
bone perimeter per area ratio (B Pm/B Ar; mm
21), trabecular
number (Tb N; mm
21) and trabecular separation (Tb Sp; mm).
In parallel, other femurs were also processed for histologic and/
or immunohistochemical studies following standard procedures.
Briefly, specimens were fixed in 10% formalin for 24 h, decalcified
in Osteosoft bone decalcifying solution (Merck KGaA, Darmstadt,
Germany) for 5 days and embedded in paraffin. Samples were cut
into 3-mm-thick sections and stained with H&E for bone histologic
evaluation or either used for immunohistochemical studies. In the
latter case, antigen retrieval was carried out in a Pascal pressure
chamber (Dako, Glostrup, Denmark) at 90uC for 20 minutes using
a Tris-EDTA buffer pH 9.0, and then tissue endogenous
peroxidase activity was quenched with a 3% H2O2 solution for
10 minutes. Sections were incubated overnight with an anti-Tcf4
antibody at 4uC and 1:20 working dilution, followed by incubation
with EnVision anti-mouse complexes (Dako). The peroxidase
activity was shown using 3,39-diaminobenzidine+ (DAB+; Dako)
as a chromogen. Finally, sections were washed in water, lightly
counterstained with hematoxylin, dehydrated and mounted in
DPX. Histologic and immunostained sections were observed with
an Olympus BX51 microscope and photographed with a Olympus
DP70 camera. Tcf4 is an activating transcription factor which
cooperatively interacts with Runx2/Cbfa1 to stimulate osteoblast-
specific osteocalcin expression [29], and thus can be used as a
bona fide marker for OB cells.
Osteoclast differentiation and pit formation assays
Peripheral blood monocuclear cells (PBMCs) from 6 healthy
donors were obtained by density gradient centrifugation using
Ficoll-Paque (r 1.073; GE Healthcare), and cultured overnight at
0.5610
6 cells/cm
2 in a-MEM medium supplemented with 10%
FBS and 100 U/mL penicillin and 100 mg/mL streptomycin.
After removal of non-adherent cells, the remainder were
maintained in the same medium but with additional 50 ng/mL
RANKL and 25 ng/mL M-CSF in the absence or presence of
dasatinib at indicated times and doses. The medium was replaced
twice weekly and cultures under each condition were performed in
quadruplicate from PBMCs of at least three different donors.
To evaluate the effect of dasatinib on OC formation, cells were
stained for tartrate-resistant acid phosphate (TRAP; leukocyte acid
phosphatase kit, Sigma), according to the manufacturer’s instruc-
tions after 21 days of culture. Using a Leica DMI6000 B inverted
microscope, TRAP+ cells containing three or more nuclei were
enumerated with the aid of a 161m m
2 grid (five randomly
selected fields/well) and photographed with a Leica DFC350FX
camera.
To test the effect of dasatinib on the bone resorption capacity of
OCs, PBMCs at 0.6610
6 cells/well were seeded on calcium-
coated slides (Becton Dickinson) in 200 ml of OC medium
supplemented with 5 ng/mL TGF-b1 (Peprotech) and 1 mM
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weekly by semi-depletion in the absence or presence of indicated
concentrations of dasatinib. At the end of the assay, cells were
removed with a 0.1% Triton X-100 solution and resorption pits
were photographed using a Leica DFC350FX camera mounted on
a Leica DMI6000 B microscope. The total resorbed area per well
was calculated using the Adobe Photoshop histogram function
(Adobe Photoshop CS2, 9.0.2). Assays were performed in triplicate
for each condition using PBMCs from five healthy volunteers.
Flow cytometry on osteoclast cells
After 2 weeks of osteoclastogenic differentiation in the absence
or presence of dasatinib, pre-OBs were trypsinized (0.25%
Trypsin-EDTA) and resuspended in Dulbecco’s PBS. Cells were
stained with anti-CD51/61-PE (aVb3 integrin-PE conjugated
Mouse IgG1) or anti-CD191-APC (CCR1-allophycocyanin con-
jugated Mouse IgG2B) for 15 minutes and subsequently with 7-
AAD for 5 minutes. After washes, cells were acquired on a
FACSCalibur flow cytometer using the CellQuest program and
analyzed with the Infinicyt software 1.3 (Cytognos, Salamanca,
Spain). Specific staining for CD51/61 or CD191 was evaluated on
7-AAD
- viable cells.
Actin ring formation assay
PBMCs were seeded at 0.5610
6 cells/cm
2 on cover slips and
cultured in the specified osteoclastogenic medium for 12–14 days
in the presence or absence of the drug. At this point, pre-OCs were
fixed in 2% paraformaldehyde for 20 minutes, permeabilized with
0.1% Triton X-100 and blocked in 5% bovine serum albumin in
PBS. Cover slips were then incubated with rhodamine-conjugated
phalloidin (1:200; Invitrogen) for 20 minutes to visualize F-actin,
and stained with DAPI to make nuclei evident. After a final rinse,
cover slips were mounted with an aqueous mounting medium
(Vector Laboratories, Burlingame, CA, USA), and the distribution
of the F-actin ring was observed with a Leica DMI6000 B
microscope and photographed with the Leica DFC350FX camera.
Assays were performed in triplicate for each condition using
PBMCs from at least three different healthy volunteers.
Statistical analysis
Each assay was performed at least three times. Quantitative
data were expressed as mean 6 SD or SEM, as specified.
Statistical comparisons using the non-parametric Mann-Whitney
U-test were considered statistically significant for values of p,0.05
(SPSS Statistics 15.0, Chicago, IL, USA).
Results
Dasatinib inhibits PDGFR-b, c-Kit and c-Src
phosphorylation and modulates downstream signaling
on osteoprogenitor cells
We first examined the effect of dasatinib on two tyrosine
kinases, PDGFR-b and c-Src, which are described targets for
dasatinib and with known involvement in mesenchymal stem cell/
osteoblast (MSC/OB) proliferation and function. PDGF is
mitogenic to mesenchymal cells while inhibiting OB differentiation
and bone matrix formation [31,32], and targeted deletion of
PDGFR-b in murine mesenchymal cells also stimulates OB
differentiation and function [33]. On the other hand, knockdown
of Src expression has also been shown to enhance OB
differentiation and function [19,34]. Serum-starved hMSC-TERT
and MG-63 cell lines (respectively representing the multipotent
MSCs and the differentiated OBs), were exposed to PDGF-BB in
the absence or presence of escalating doses of dasatinib to check
for potential differences in sensitivity due to their differentiation
status. As illustrated in Figure 1A, PDGF-BB exposure markedly
increased PDGFR-b tyrosine phosphorylation in both cell lines,
and dasatinib strongly diminished PDGF-stimulated PDGFR-b
activation. PDGF-BB treatment also increased basal p-Y416 of c-
Src, ascribable to PDGFR-b activation and its interaction with the
Src family kinases [35]. Dasatinib treatment only partially
abrogated both basal and PDGF-induced c-Src activation in the
hMSC-TERT, while inhibition of c-Src phosphorylation was
more pronounced in the MG-63 cell line (Figure 1A). We also
show that both cell lines express c-Kit, the stem cell factor (SCF)
receptor for which dasatinib also presents inhibitory activity
[10,36]. SCF-induced c-Kit phosphorylation is efficiently dimin-
ished by dasatinib in both cell lines (Figure 1A).
To gain some insight into the mechanisms underlying the effect
of dasatinib on these cells, we explored the activation status of key
molecules in signaling pathways downstream the affected tyrosine
kinases, such as: Erk1/2, Akt, and p38 mitogen activated protein
kinase (MAPK). As observed in Figure 1B, dasatinib inhibits
PDGF-induced Akt activation in the hMSC-TERT and even
more effectively in the MG-63 cell line. Inhibition of PDGF-
induced PI3-kinase/Akt activation has been shown to promote
osteogenic differentiation and mineralized-matrix production in
osteogenic cultures [11,37], and a similar effect could be expected
from dasatinib in our experimental settings. On the other hand,
dasatinib induced a remarkable inhibition of Erk 1/2 phosphor-
ylation only in the MG-63 cell line and failed to modulate p38
activation in neither cell line. Although activation of Erk 1/2 and
p38 have been reported to promote OB differentiation and matrix
mineralization through Osterix [38,39], at least in our experi-
mental settings, dasatinib does not seem to stimulate the
osteogenic differentiation and function by similar molecular
mechanisms.
Dasatinib inhibits osteoprogenitor cell and osteoblast
proliferation
OBs are derived from precursor MSCs, a process which implies
reduction of their proliferative and stem cell self-renewal capacities
while acquisition of OB-specific features and lineage commitment
[31]. We therefore first tested the effect of dasatinib on the growth
rate and viability of OB cells and their mesenchymal progenitors.
As seen in Figure 2A, the number of cells in both the hMSC-
TERT and MG-63 cultures was progressively reduced with
increasing doses of dasatinib. We further studied the effect of
increasing dasatinib concentrations on the number of viable cells
at different times along the osteogenic differentiation process. A
dose and time-dependent reduction on the number of viable cells
was observed as referred to the absence of the drug (control) at
each time point, which was especially evident at the end of the
differentiation period (21 days) and with dasatinib concentrations
$10 nM (Figure 2B). Also, OBs derived from primary MSCs
resulted more sensitive to higher dasatinib doses than OBs derived
from the hMSC-TERT cell line (Figure 2B, left graph vs right
graph), with no significant differences in the number of viable OBs
derived from MM patients and healthy donors (data not shown).
It is likely that the reduced number of viable cells in osteogenic
cultures after dasatinib treatment could be majorly ascribed to
reduced cell proliferation and/or increased apoptosis. Using the
hMSC-TERT cell line and a 7-day culture period, we show that
dasatinib effect until a 50 nM dose was mainly due to a reduced
proliferative capacity (Figure 2C, left) as assessed by reduced
number of cell divisions when increasing dasatinib concentration.
The percentage of apoptotic and/or necrotic hMSC-TERT cells,
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dasatinib doses (Figure 2C, right). Our results are therefore
consistent with those of other authors which have found that
dasatinib inhibits osteoprogenitor cell proliferation [19] and
induces apoptosis with higher doses of the drug ($100 nM) [20].
Importantly, the number of viable cells in OBs derived from
primary MSCs (either from MM patients or healthy donors) after
the 21-day differentiation period was more pronouncedly
diminished as compared to OBs derived from the hMSC-TERT
cell line (Figure 2B, left graph vs right graph). This issue should be
taken into account if dasatinib is used for the treatment of human
primary osteoprogenitor cells, in order to achieve a compromise
between dasatinib inhibition of cell proliferation and its osteogenic
potential. In fact, the use of high dasatinib concentrations might
have been the reason why some authors failed to observe an
osteogenic effect on human MSCs with this drug [22]. In the light
of these observations and for next experiments, we decided to
restrict the use of dasatinib concentrations to the low nanomolar
range (#5 nM).
Low dasatinib concentrations promote osteogenic
differentiation, alkaline phosphatase and Runx2/Cbfa1
activities and matrix mineralization
Since OB maturation implies a balance between proliferation
and differentiation, it could be hypothesized that inhibition of
osteoprogenitor proliferation by dasatinib would correlate with an
enhanced osteogenic differentiation. We evaluated whether
dasatinib was capable of modulating osteogenic gene expression
in OBs derived from primary MSCs at the selected low
concentrations (2–5 nM). Expression of bone-formation markers
such as alkaline phosphatase (ALP), collagen I type A 1 (COLIA1)
and the transcription factors Runx2/Cbfa1 and Osterix was
evaluated by real time RT-PCR and analyzed at either day 7 or
14 of the differentiation process [40]. Figure 3A shows that
dasatinib clearly increased the expression of the osteogenic genes
to levels higher than those observed in the same conditions but in
absence of the drug (control). Interestingly enough, this effect was
not restrained to MSCs from healthy volunteers, but MSCs from
myeloma patients also responded to dasatinib in a similar way
(Figure 3A), thereby supporting the osteoblastogenic therapeutic
potential of dasatinib in this disease.
We also examined the biological effect of dasatinib in promoting
osteogenic differentiation by measuring ALP and the transcription
factor Runx2/Cbfa1 activities as well as mineralized-matrix
formation, in OBs differentiated from primary MSCs and from
the hMSC-TERT cell line. Dasatinib (at 2 nM or 5 nM) was
added to the osteogenic medium at the initiation of OB
differentiation, and ALP and Runx2/Cbfa1 activities were
measured as surrogates of OB activity at day 7 and 14,
respectively. Dasatinib significantly and dose-dependently in-
creased ALP activity even in OBs derived from primary MSCs
(Figure 3B, upper). Also Runx2/Cbfa1 activity measured in
nuclear lysates of pre-OBs was augmented in the presence of
dasatinib, although the increase was not statistically significant in
OBs derived from healthy donors (Figure 3B, lower). To estimate
matrix mineralization, alizarin red staining and dye quantification
were performed after a 21-day osteogenic differentiation of MSCs.
Under the aforementioned conditions, OBs derived from the
hMSC-TERT cell line underwent a clear dose-dependent increase
in mineralization (Figure 3C, left); a slight but reproducible trend
towards increased matrix mineralization was also observed in OBs
derived from primary MSCs from healthy volunteers and
myeloma patients, although it did not reach significance in the
latter (Figure 3C, right).
The Wnt/b-catenin signaling pathway is known to play a key
role in the osteogenic differentiation of mesenchymal progenitors
and in normal skeletal development [41]. Therefore, we examined
whether the activity of dasatinib in our experimental setting was
accompanied by downstream activation of the canonical Wnt
signal transduction. As observed in Figure 3D by immunoblot
analysis, dasatinib clearly induced accumulation of the active
dephosporylated form of b-catenin in the nuclear compartment,
whereas levels of the inactive phosphorylated form in the
cytoplasm were reduced. Taken together, our data show that the
MSC/OB lineage expresses tyrosine kinases such as PDGFR-b,c -
Src, and c-Kit, whose activation can be partially inhibited by low
doses of dasatinib (#5 nM). Within the same range of dasatinib
concentrations, these effects are associated with activation of
canonical Wnt signaling.
Figure 1. Dasatinib inhibits PDGFR-b, c-Kit and c-Src phosphorylation in mesenchymal and osteoblast-like cell lines. (A) Mesenchymal
(hMSC-TERT) and osteoblast-like (MG-63) cell lines were pretreated with different concentrations of dasatinib for 6 hours and then exposed to PDGF-
BB or SCF for 20 minutes before protein lysates were generated. Immunoblotting with specific antibodies against total and phosphorylated PDGFR-b,
c-Kit and c-Src were performed. (B) Modulation of downstream signaling after dasatinib treatment. Similarly to experimental conditions in (A), the
hMSC-TERT and the MG-63 cell lines were pretreated with 50 nM dasatinib for 6 hours, stimulated with PDGF-BB for 20 minutes and then cell
harvested for protein isolation. Immunoblotting is shown for total and phosphorylated forms of PDGFR-b, c-Src, Erk 1/2, Akt and p38 mitogen
activated protein kinase (MAPK).
doi:10.1371/journal.pone.0034914.g001
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34914Figure 2. Dasatinib reduces the number of viable cells by inhibition of mesenchymal and OB cell proliferation. (A) Dasatinib decreases
the number of MSC and OB cells in culture. The hMSC-TERT and the MG-63 cell lines were cultured for 7 days in maintenance medium in the absence
or presence of increasing dasatinib concentrations, and then the number of cells at each condition was counted with a haemocytometer and a
Trypan Blue solution. Representative micrographs are shown. (B) Dasatinib reduced the number of viable cells in osteogenic cultures in a time and
concentration-dependent manner. MSCs were maintained in osteogenic medium for 7, 14 or 21 days in the presence of different dasatinib
concentrations, and percentage of viable cells was evaluated with the alamarBlue assay on OBs derived from the hMSC-TERT (left) and from primary
MSCs from MM patients (right). Data are expressed as the mean 6 SD from three experiments. Statistically significant differences from control are
indicated as *P,0.05. (C) Dasatinib (5–50 nM) reduces the number of cell divisions in the hMSC-TERT cell line (left) but does not induce apoptosis
(right). MSCs were stained with PKH67 and cultured in osteogenic medium for 7 days in the absence or presence of dasatinib; at the time of
collection, cells were also stained with Annexin-V-PE and 7-AAD and analyzed by flow cytometry.
doi:10.1371/journal.pone.0034914.g002
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34914Figure 3. Dasatinib promotes osteogenic differentiation of MSCs from MM patients and healthy donors and of the hMSC-TERT cell
line. (A) Dasatinib upregulates the expression of bone-formation markers in the osteogenic differentiation process. Primary MSCs from MM patients
and healthy donors were cultured in osteogenic medium in the presence (2–5 nM) or absence of dasatinib, and total RNA was isolated on days 7 and
14. Real-time qRT-PCR was used to determine the expression of several OB related markers: ALP was determined at day 7, whereas the transcription
factors Runx2/Cbfa1 and Osterix (Osx), and collagen I type A 1 (COLIA1) were measured at day 14. Expression levels for each gene were normalized to
GAPDH expression and referred to those in the absence of dasatinib. Graphs illustrate mean values from samples from 5 healthy donors and 5 MM
patients 6 SEM (bars)* P,0.05. (B) Dasatinib increases ALP and Runx2/Cbfa1 activities in osteoprogenitor cells. In the hMSC-TERT cell line and in
primary hMSCs derived from three myeloma patients and three healthy donors, ALP activity was measured at day 7 (upper graph) and Runx2/Cbfa1
activity was measured at day 14 (lower graph) after the addition of dasatinib to the osteogenic differentiation medium. Data are represented as the
mean 6 SD from three experiments. (C) Dasatinib (2–5 nM) augments bone matrix mineralization in OBs derived from the hTERT-MSC cell line (left) or
MSCs from healthy donors and myeloma patients (right), as assessed by alizarin red staining quantification. Data are represented as the mean 6 SD
from three experiments with the hMSC-TERT cell line, and as the mean (5 MM patients and 5 healthy donors) 6 SEM in experiments with primary
MSCs. Statistically significant differences from controls are indicated as *, where P , 0.05. Micrographs show matrix mineralization after alizarin red
staining of correspondent differentiated OBs. (D) Both dephospho- and phospho-b-catenin levels were determined by immunoblotting in cytosolic or
nuclear lysates of pre-OBs differentiated from the hMSC-TERT cell line in the absence or presence of dasatinib. Histone H1 and a-tubulin were used as
loading controls for nuclear or cytosolic protein fractions.
doi:10.1371/journal.pone.0034914.g003
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Consistent with our in vitro findings, we corroborated the bone
anabolic properties of dasatinib in the in vivo setting. To better
discern the putative bone formation effect of dasatinib from its
known inhibitory activity on OC formation and function, we used
skeletally-immature 5 week-old healthy mice which present very
active bone formation and minimal bone resorption. Two different
doses of dasatinib (2.5 mg/kg vs 10 mg/kg) administered twice-a-
day (BID) and two periods of dasatinib treatment (3 vs 7 weeks)
were compared in order to evaluate potential osteogenic/anti-
proliferative activities of the drug on endogenous osteoprogenitor
cells, as we had observed in vitro for primary MSCs. Being ALP an
early marker of bone formation, Figure 4A shows that ALP levels
in serum were significantly increased in mice treated with both
doses of dasatinib after 3 weeks of treatment, whereas ALP levels
remained unaffected with respect to vehicle-treated animals at
longer treatment periods. Relative to osteocalcin (also a bone
formation marker, but expressed at later stages of OB differen-
tiation), significant increases in serum were observed for both doses
of dasatinib after 3 weeks and even further increments were
attained in a 7-week period. Minimal differences were found in
osteocalcin serum levels between the 2.5 mg/kg BID and 10 mg/
kg BID doses, neither after 3 weeks nor after 7 weeks of treatment,
which probably reflects a near to plateau-effect on osteocalcin
induction with the doses in our study. Due to the use of young
healthy mice with limited OC function, no changes on levels of
TRAP5b (a surrogate marker for OC number) were measured
between baseline and after 3 or 7 weeks of treatment (Figure 4C).
This is in accordance with a very scarce presence of OCs observed
in the histological sections from femurs of control animals along
the experiment (data not shown).
The effects of both doses of dasatinib were also evaluated by
quantitative micro-CT scanning of distal femurs of treated mice.
As observed in Figure 4D, dasatinib treatment led to a marked
increase in trabecular microarchitecture of cancellous bone in a
dose- and time-dependent manner. This effect was associated to
significant increases of trabecular number (Tb N; mm
21) and of
the ratio of bone perimeter per bone area (B Pm/B Ar; mm
21),
together with decreased trabecular separation (Tb Sp; mm)
compared with vehicle-treated animals (Figures 4E-G). The effects
of dasatinib on increased trabecular structures were more
pronounced for the 10 mg/kg BID and the 7-week period
treatment as compared to the rest of the experimental conditions.
The increased trabecular number was equally apparent by
histologic observation of newly formed trabeculae at the
epiphyseal plate (Figure 4H), and also correlated with increased
number and intensity of staining of Tcf4 positive OB-like cells
lining the trabecular borders (Figure 4I). The transcriptional
activation of target genes by Tcf transcription factors mediates the
activation of the canonical Wnt/b-catenin signalling pathway,
which is essential in OB differentiation [41]. Specifically, within
the Tcf family members, Tcf4 is the one most abundantly
expressed in OB cell lines and primary human MSCs [42];
therefore, the increased number and intensity of Tcf4 positive cells
may well reflect an increased number of active OBs after dasatinib
treatment.
Dasatinib inhibits osteoclast formation and activity
We first confirmed the inhibitory effect of dasatinib in
osteoclastogenesis (Figure 5A) and OC function (Figure 5B), as
has already been reported for this drug [17,18]. For this purpose,
PBMCs from healthy volunteers were incubated in an M-CSF/
RANKL-containing medium for 21 days, and dasatinib was
added throughout the differentiation process or on days 7–21 or
14–21. As seen in Figure 5A, when dasatinib was present for
21 days, it markedly reduced OC numbers in a dose-dependent
fashion (IC50=2.16 nM; P,0.05 at $1n Mvs. control). When
dasatinib was added to early OC progenitors (day 7) or to
committed OC precursors (day 14) it was also effective in reducing
osteoclastogenesis, although higher doses were required: IC50
=3.14 nM; P,0.05 at $2.5 nM vs control (7–21 days); IC50
=5.62 nM; P,0.05 at $ 2.5 nM vs control (14–21 days). Notably,
the number of OCs was markedly reduced at higher doses of
dasatinib (Figure 5A, e.g., $5 nM dasatinib, 1–21 days). This
could be explained by a toxic effect of dasatinib on OC
progenitors at those doses, but it may well also reflect that
dasatinib is targeting essential pathways for OC viability.
Figure 5B shows the area of resorptive pits. Progressive
substantial reductions of resorbed lacunae were observed with
increasing dasatinib concentrations, resorption being almost
completely abrogated at a concentration of 2.5 nM. Of note, this
effect of dasatinib on OCs is achieved within similar low doses of
dasatinib (low nanomolar range) as for its activity in promoting in
vitro osteogenic differentiation from mesenchymal precursors.
Thus, in vitro doses of 2–2.5 nM dasatinib on OCs are sufficient
for inhibition of OC formation to a 20% of the control and to
reduce the resorptive activity further to a 5% of the control, and
would not interfere with the osteogenic activity of this compound.
Mechanism of action of dasatinib on osteoclasts
We first assessed that the low concentrations of dasatinib
capable of reducing OC formation and resorption in our previous
experiment (1–2 nM) were also effective in inhibiting the
activation of the M-CSF receptor, c-Fms, in OCs (as is shown in
Figure 6A). Since M-CSF and RANKL are the two main
proliferation and survival factors involved in osteoclastogenesis
from monocyte/macrophage precursors, the c-Fms kinase has
been considered as a major target of dasatinib on OCs [17,18].
However, since dasatinib is capable of inhibiting OC formation
when not present throughout the differentiation process but also at
later stages of OC differentiation (days 7–21 and 14–21;
Figure 5A), together with the fact that OC resorption is more
effectively reduced than OC formation (Figure 5A vs 5B),
indirectly suggests that inhibition of additional tyrosine kinases
other than c-Fms, are also contributing to dasatinib effects on this
cell type. Figure 6A shows that in OC precursors, even at doses as
low as 1 or 2 nM, dasatinib is capable of inhibiting the activation
of two other tyrosine kinases, such as c-Src and c-Kit. The c-Src
kinase is an essential molecule for OC resorption, intervening in
the aVb3 integrin outside-in signaling in the sealing zone between
the OC and the bone matrix [43]; in accordance with these
observations, c-Src
-/- mice show an osteopetrotic phenotype with
OCs unable to form ruffled borders despite a normal morpholog-
ical appearance [44]. Thus, inhibition of this tyrosine kinase by
dasatinib would greatly compromise OC functionality. On the
other hand, the ligand for c-Kit, the SCF, has been shown to be
mitogenic for OC precursors and to promote mature OC activity
[45]. Inhibition of signaling through c-Kit by dasatinib may
therefore also play a role in inhibition of osteoclastogenesis and
diminished OC resorption.
Besides, when analyzing the expression of several key molecules
implicated in OC commitment/differentiation/function, we were
able to identify further and novel consequences of dasatinib
treatment on this cell type. As shown in Figure 6B, in early OC
progenitors (day 4 since initiation of in vitro differentiation)
dasatinib does not affect levels of PU.1, which is a transcription
factor that regulates the commitment of myeloid cells to common
progenitors for macrophages and OCs [45]. At a later stage of OC
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slight inhibition of p-Erk 1/2, and specifically, a marked reduction
of c-Fos levels. Notably, c-Fos is a key regulator of OC
differentiation and is clearly required for osteoclastogenesis
[45,46]. Mice lacking c-Fos develop osteopetrosis due to defective
OC differentiation, whereas the number of macrophages increases
[46,47]. We also show that NFATc1, a major transcription factor
integrating RANKL signaling in terminal differentiation of OCs
[45,48] is retained in the cytoplasmic fraction while nuclear
NFATc1 levels are diminished after dasatinib treatment for 7 days
(Figure 6B). NFATc1 requires dephosphorylation and nuclear
translocation to activate the transcription of OC-specific genes
[49], and thus the diminished transcriptional activity of NFATc1
would likely contribute to the inhibitory effects of dasatinib in OC
differentiation. Besides, in late OC precursors (day 14, prefusion
OCs and multinucleated OCs), dasatinib treatment reduces the
expression of cathepsin K, which is the major cysteine protease in
OCs implicated in degradation of organic cellular matrix during
bone resorption [43]; therefore, our data provide another
mechanism by which dasatinib may inhibit OC resorption.
Furthermore, dasatinib treatment on OCs was also associated to
a clear reduced expression of the aVb3 integrin and of CCR1
(Figure 7A, B), and to disruption or even absence of the F-actin
ring in most multinucleated OC precursors (Figure 7C). The aVb3
integrin mediates the interactions between OCs and the
extracellular matrix, and is therefore implicated in cell adhesion,
regulation of OC migration and bone resorption [43]. The
reduced levels of aVb3 together with inhibition of c-Src activation,
would likely account for the disruption of the F-actin ring, which is
necessary for the maintenance of the sealing zone and an effective
bone resorption [50]. Also, CCR1 is the major receptor for CCL3
(MIP-1a), a pro-inflammatory cytokine that induces osteoclasto-
genesis and stimulates OC activity [51–53]. It is therefore
conceivable that downregulation of CCR1 by dasatinib would
further sustain dasatinib inhibitory effects in OC formation and
resorption. Taken together, we could say that at very low
concentrations (1–2 nM) dasatinib is capable of targeting various
tyrosine kinases (including c-Fms, c-Src, c-Kit), which by several
avenues lead to a profound inhibition of osteoclastogenesis and of
OC function.
Discussion
Mesenchymal stem cells from the bone marrow may under
specific conditions differentiate into osteoblasts, adipocytes,
chondrocytes, tenocytes, skeletal myocytes and cells of visceral
mesoderm [54,55]. Considerable interest has been raised in recent
years for the use of MSCs for repair and regeneration of a number
of tissues including bone [56–59]. Moreover, the possibility of
pharmacologic agents targeting this population of progenitor cells
to specifically enhance their differentiation into the osteogenic
Figure 4. Dasatinib promotes trabecular bone formation in vivo. (A, B, C) Five-week-old CD1 mice were treated with vehicle (control) or with
dasatinib in a 2.5 mg/kg BID or a 10 mg/kg BID regimen for 3 or 7 weeks, and serum levels were determined for ALP (A), osteocalcin (B) or TRAP5b (C)
before initiation of the experiment and at each time point. Graphs are plotted as mean values of fold change from baseline levels for the mentioned
factors in sera 6 SEM (bars). *, P,0.05 indicates significant differences between levels for each time and dose of dasatinib and untreated mice at the
same conditions (control). (D) Representative micro-CT analyses of equivalent cross-sections of distal femurs are shown for each dasatinib
concentration and time of treatment. (E, F, G) Trabecular bone morphometric parameters from micro-CT images were quantitated by CT-Analyser
software for bone perimeter per area (E), trabecular number (F) and trabecular separation (G). *, P,0.05 relative to vehicle control at each time-point;
n=3 femurs per group. (H) Representative femur sections treated with both dasatinib doses for 3 weeks and stained with hematoxylin and eosin.
Bar=50 mm. (I) Representative images of Tcf4 immunohistochemistry in dasatinib-treated femurs for 7 weeks. OB-like cells immunostained for Tcf4
can be observed lining the trabeculae (arrows). Bar=12.5 mm.
doi:10.1371/journal.pone.0034914.g004
Figure 5. Dasatinib treatment inhibits OC formation and resorption activity. (A) PBMCs from healthy donors were cultured in medium
containing M-CSF/RANKL for 21 days in the absence or presence of dasatinib for the indicated times, and OCs were counted (as assessed by TRAP+
staining and the presence of more than three nuclei). Representative micrographs of TRAP staining for OCs treated with dasatinib for 3 weeks are
shown. Bar=0mm. (B) OCs were generated on calcium-coated slides, and the effect of different dasatinib concentrations on OC resorption was
evaluated by calculation of the total area of resorbed lacunae. Graphs represent mean values of samples from OCs derived from three healthy donors
6 SEM (bars). *, P,0.05 indicates significant differences between dasatinib-treated cultures and untreated control at the same conditions.
Representative micrographs of resorbed lacunae on the calcium-coated wells are shown. Bar=30mm.
doi:10.1371/journal.pone.0034914.g005
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regenerative medicine.
In concordance with these expectations and also in line with
previous data from other groups [19–21], we were able to observe
that dasatinib treatment effectively promoted the osteogenic
differentiation of mesenchymal progenitors (both primary bone
marrow MSCs and the hMSC-TERT cell line) as observed by
increased ALP and Runx2 activities, augmented matrix mineral-
ization and elevated expression levels of genes associated with OB
differentiation (Runx2/Cbfa1, Osterix, ALP and COLIA1). We
have also shown that MSCs and OBs express various tyrosine
kinases such as PDGFR-b, c-Src and c-Kit, and although with
some differences in sensitivity between MSCs or differentiated
OBs, dasatinib at low concentrations (#5 nM) was capable of
partially inhibiting their phosphorylation. It is likely, therefore,
that concomitant inhibition of these three kinases might be
mediating the osteogenic differentiation in our experimental
conditions. Other authors have linked the enhanced OB
differentiation of dasatinib to its inhibitory activity on the c-Src
kinase [19,20] and on the Abl kinase [19]. We and others have
shown that dasatinib promotion of OB differentiation and function
relies on inhibition of cell proliferation at lower doses [19] and to
Figure 6. Dasatinib regulates the expression of important molecules/factors for OC formation, differentiation and activity. (A)
Dasatinib inhibits c-Fms, c-Src, and c-Kit tyrosine kinase phosphorylation in committed OC precursors. PBMCs were differentiated in osteoclastogenic
medium for 7 days, pretreated with 1 nM or 2 nM dasatinib or vehicle, and exposed to 50 ng/mL M-CSF or 50 nM SCF for 20 minutes prior to protein
isolation. Immunoblotting with specific antibodies was performed as indicated. (B) PBMCs were maintained in osteoclastogenic medium for indicated
times in absence or presence of 1 nM or 2 nM dasatinib. Immunoblots are shown for PU.1, Erk1/2, p-Erk1/2, c-Fos, NFATc1 (both in nuclear and
cytoplasmic protein fractions) and cathepsin K.
doi:10.1371/journal.pone.0034914.g006
Figure 7. Further consequences of dasatinib treatment on OC function. Expression of aVb3-integrin (CD51/61) (A) and CCR1 (CD191) (B) was
evaluated by flow cytometry in pre-OCs after culture in an osteoclastogenic medium in the absence or presence of dasatinib for 2 weeks. Graphs
represent the mean values of the median fluorescence intensity (MFI) percentage from OCs derived from three healthy donors 6 SD (bars). *, P,0.05
indicates significant differences between dasatinib-treated cultures and untreated control. (C) The integrity of the F-actin ring in multinucleated OC
precursors (obtained like in A and B) was evaluated by phalloidin-rhodamine staining, whereas nuclei were visualized with DAPI. Representative
micrographs for each condition are reported. Bar=50 mm.
doi:10.1371/journal.pone.0034914.g007
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observed that primary MSCs (both from normal donors and
myeloma patients) are more sensitive to this effect of dasatinib than
the hMSC-TERT cell line, it is worth to mention that if dasatinib
is used in the clinical setting to pursue an osteogenic effect, special
precaution should be taken to achieve a compromise within
reduced osteoprogenitor cell numbers and enhanced osteogenic
differentiation.
Interestingly, and in support of our in vitro observations on the
osteogenic promotion activity of dasatinib, these effects were also
reflected in our in vivo model. Specifically, 5-week-old skeletally-
immature mice with very active bone formation and minimal bone
resorption were used, so that the effect of dasatinib on bone could
be majorly ascribed to its action on OBs and not to inhibition of
OC formation and function. Our data showed that both doses of
dasatinib were associated with significant increases of trabecular
architecture parameters (as calculated from micro-CT analyses)
and a higher number of trabeculae on histologic sections of
cancellous bone in distal femurs. Although the increased
trabecular structures could also result from the inhibitory effect
of dasatinib on OC formation and resorption, the augmented
serum levels of bone formation markers (ALP, osteocalcin), the
increased number and activation of OB-like cells (as observed by
Tcf4 immunostaining), together with absence of significant
changes in serum TRAP5b levels (as a surrogate for OC number),
lead us to conclude that in our model the augmented trabecular
formation after dasatinib treatment is majorly attributable to
increased OB formation and activity rather than to an inhibitory
effect on OCs. It should also be noted that both doses used in our
in vivo study are relatively low as compared to those used for this
drug in mouse models of tumor malignancies, and near the
considered minimum efficacious doses of dasatinib (1.25 mg/kg
BID or 2.5 mg/kg once a day) [60]. From preliminary studies
(data not shown), we know that levels of bone formation markers
(ALP, osteocalcin) were not increased as compared to controls in
mice treated with a higher dose of dasatinib (25 mg/kg, BID,
5 days/week), which in line with our in vitro studies, highlights the
importance of maintaining a low and constant concentration of
dasatinib to promote the osteogenic differentiation of osteopro-
genitors. It should be mentioned that in another model of
physiological bone turnover, skeletally-mature 9-month-old rats
were treated with a dasatinib dose of 5 mg/kg once a day (thus
quantitatively equivalent to our low dose of 2.5 mg/kg on a BID
regimen). Serum OB markers were not significantly altered in this
study [61], and increases in tibial trabecular bone volume in the
rat model were attributed to dasatinib inhibition of OC activity.
This discrepancy in both in vivo models may be explained by
species differences in sensitivity of osteoprogenitor cells to
dasatinib, but also likely to differences in experimental models.
Consequently with our observations, the capacity of dasatinib to
target bone marrow MSCs and to promote their osteogenic
differentiation could be used in the biologic repair of skeletal
defects of traumatic origin. For instance, dasatinib could be used
as an adjuvant therapy to promote endogenous MSC osteogenic
differentiation and accelerate bone fracture healing and bone
implant fixation. Moreover, dasatinib treatment after establish-
ment of MSC-based bone grafts could improve bone repair and
regeneration in the field of orthopaedic surgery.
On the other hand, we were able to confirm the inhibitory
effects of dasatinib on osteoclastogenesis and OC resorption in vitro
[17,18]. These effects were achieved at very low doses (1–2 nM),
and in fact we showed that these concentrations were effective in
inhibiting the activation of c-Fms, c-Src and c-Kit (Figure 6A)
which are essential tyrosine kinases for OC differentiation and
function. When analyzing the expression of several key molecules
in the presence of these low dasatinib concentrations, we were able
to identify further and novel consequences of dasatinib treatment
which would probably contribute to inhibition of OC differenti-
ation (such as reduced c-Fos levels and NFATc1 levels in the
nuclear compartment, as well as diminished expression of the
CCR1 receptor), and to impair OC resorption (reduced avb3
integrin, CCR1 and cathepsin K protease expression, and F-actin
ring disruption). Therefore, dasatinib treatment would by several
mechanisms lead to a profound inhibition of OC formation and
OC function. As previously mentioned, dasatinib inhibitory effect
on OCs has also been shown in an in vivo model [61].
It is noteworthy to mention that our inhibitory in vitro effects of
dasatinib on OC formation and function were achieved within the
same low nanomolar range (#5 nM) of concentrations at which
dasatinib promoted the in vitro osteogenic differentiation from
mesenchymal precursors. Besides, those doses have been reported
to be safe and therapeutically achievable in pharmacological
studies [60,62]. In our in vivo model, we have shown effective bone
anabolic effects targeting the osteoprogenitor population also at
relatively low dasatinib concentrations (2.5 mg/kg–10 mg/kg)
[60]. This likely suggests that there is a therapeutic dosage
window of easily pharmacologically achievable low dasatinib
concentrations in which concurrent bone formation would be
enhanced and bone resorption would be impaired, thus making
dasatinib a potential attractive pharmacological approach for the
treatment of bone diseases coursing with bone loss and in which
both of these processes are affected. In osteoporosis, progressive
bone loss results because the osteoblastic activity cannot
compensate for excessive bone resorption. Although the standard
of care for osteoporosis patients has traditionally relied on anti-
resorptive drugs [1,63], last decade advances in the knowledge of
bone biology have highlighted the need for additional anabolic
treatments in this disease, and several agents, including calcilytic
drugs and antagonists of Wnt inhibitors (such as antibodies against
sclerostin and anti-DKK1) are now being evaluated in clinical
trials (reviewed in [1]). It can be envisioned that the simultaneous
bone-forming and anti-resorptive effects of low doses of dasatinib
may well be exploited for the treatment of this disease. Also, in
osteolytic-type tumor metastases (most common in metastasis of
breast, lung and renal cancer), the enhanced differentiation and
resorption activity of OCs, is also accompanied by suppressed OB
formation due to DKK-1 secretion from tumor cells [3,64].
Therefore, convergent anabolic and anti-resorptive activities of
dasatinib could be investigated for beneficial impact as an
adjuvant treatment besides regular tumor chemotherapy in
metastatic skeletal osteolytic lesions.
The potential therapeutic use of dasatinib as an adjuvant
therapy in myeloma-associated bone disease deserves a separate
comment. The osteolytic lesions in MM are also characterized by
augmented OC numbers and resorption and almost suppressed
osteoblast OB differentiation and bone formation [5,65]. The
interaction of myeloma cells with stromal and osteoprogenitor cells
in the bone marrow leads to the overexpression of multiple OC
activating factors (including RANKL, CCL3, IL-3, osteopontin,
IL-6 and vascular endothelial growth factor; in turn, OCs also
support myeloma proliferation and survival by production of
myeloma growth factors such as IL-6, B-cell-activating factor, and
a proliferation inducing ligand [4]. The very potent inhibitory
effects of dasatinib on osteoclastogenesis and OC function [17,18]
and our own data strongly support that dasatinib would greatly
reduce OC numbers and resorption in the context of myeloma
bone disease. Besides, we have shown that dasatinib treatment
reduces CCR1 expression on late OC precursors (Figure 7B),
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stimulator of osteoclastogenesis and of OC function in MM
[51,52]. This would therefore further support an inhibitory
resorptive effect of dasatinib in the context of myeloma bone
disease. On the other hand, reduced osteoblastogenesis in MM
relies on abnormal (genetic, functional and phenotypical) proper-
ties and impaired osteogenic potential of osteoprogenitor cells
from myeloma patients [7,25,66,67], together with production of
multiple osteoblastogenesis inhibitors by myeloma cells and the
microenviromental cells within the myelomatous bone [5,68,69].
Interestingly, in the present report we have shown that bone
marrow MSCs from MM patients, although having a reduced
osteogenic capacity [7] are also capable to respond to dasatinib
and differentiate to OBs in a similar way as those from normal
donors. Preclinical efficacy of dasatinib in multiple myeloma, with
specific inhibition of proliferation of myeloma plasma cells and
angiogenesis has already been reported [70]. It should be noted,
however, that both the in vitro stimulatory action of dasatinib on
MSCs from myeloma patients as well as its inhibitory effect on OC
formation and function are attained at doses in the low nanomolar
range (2–5 nM), which are subapoptotic for myeloma cells
(IC50=25–100 nM) and for inhibition of angiogenesis
(IC50=50 nM) [70]. Thererefore, if dasatinib at low doses is to
be used in multiple myeloma for a beneficial effect on osteolytic
lesions it should be added as a supportive therapy together with
other pharmacological agents targeting myeloma growth. Current
standard management of MM bone disease relies primarily on
bisphosponates (pamidronate, ibandronate, zolendronic acid),
which are strong bone-resorption inhibitors but do not stimulate
bone formation [71], and may induce adverse side effects such as
osteonecrosis of the jaw and renal impairment [72]. Although
bisphosphonates are very effective in reducing skeletal complica-
tions, bone disease still progresses at a slower rate, which highlights
the importance of the clinical incorporation of strategies that may
not only impede bone degradation but also promote an anabolic
bone effect in multiple myeloma [4,68]. In line with these
treatments, our data strongly suggest that dasatinib at low doses
may be a valuable adjuvant therapy for the treatment of myeloma-
associated bone disease.
In summary, our results provide evidence that low dasatinib
concentrations (2–5 nM) are capable of in vitro promoting the
osteogenic differentiation and OB activity of primary MSCs,
including those derived from MM patients. A bone anabolic effect
of dasatinib was also observed in a skeletally-immature mouse
model with relatively low doses of dasatinib (2.5 mg/kg BID and
10 mg/kg BID), as assessed by increased trabecular structures,
elevated serum levels of bone building markers and higher number
of active OBs; since no significant changes were found in sera for
TRAP5b (a surrogate marker for the number of OCs), the
increased bone trabeculae were ascribed to the promotion of OB
differentiation and enhanced activity of endogenous mesenchymal
progenitors. In addition, in the same range of low nanomolar
concentrations, we showed that dasatinib is capable of hindering in
vitro osteoclastogenesis and resorption activity and of inhibiting the
activation of c-Fms, c-Src and c-Kit kinases. Some of the
molecular mechanisms mediating these effects on the OC
population have also been identified in this study, including some
inhibiting OC differentiation (reduced c-Fos and nuclear NFATc1
levels) and function (reduced expression of avb3, CCR1, cathepsin
K and F-actin ring disruption). Therefore, our data confirm and
provide new insights of dasatinib at low doses as a bone modifying
agent with convergent bone anabolic and anti-resorptive effects at
therapeutically and safe achievable concentrations. Specifically,
dasatinib at low concentrations might be used as an adjuvant
therapy to promote the osteogenic differentiation of endogenous or
ectopically implanted MSCs. Also, dasatinib holds promise to be
therapeutically beneficial for bone disorders coursing with
augmented bone resorption and inhibited bone formation, such
as osteoporosis, osteolytic tumor metastasis and myeloma bone
disease.
Acknowledgments
The authors thank Montserrat Martı ´n, Susana Fraile (CIC-IBMCC),
Isabel Isidro, Teresa Prieto, Almudena Martı ´n and Sandra Muntio ´n
(Hospital Universitario de Salamanca), for their excellent technical work
and expertise. We are also thankful to Drs Norma Gutie ´rrez and Lucı ´a
Lo ´pez, Hospital Universitario de Salamanca, for follow-up of MM patients
participating in the study. We are indebted to Drs Carlos Ortiz de
Solo ´rzano and Laura Guembe, Centro de Investigacio ´n Me ´dica Aplicada
(CIMA) of the Universidad de Navarra (Spain), for micro-CT and
immunohistochemical analyses, as well as to M
a Victoria Barbado,
Universidad de Salamanca, for histologic processing of undecalcified
femur samples.
Author Contributions
Conceived and designed the experiments: AG-G EMO CS JFB FMS-G
FYL AP JFSM MG. Performed the experiments: AG-G EC CS PH-C
RMF-H MG. Analyzed the data: AG-G EMO AP MG. Contributed
reagents/materials/analysis tools: CS JFB. Wrote the paper: AG FMS-G
JFSM MG. Performed histological studies: TH-I JGB.
References
1. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future.
Lancet 377: 1276–1287.
2. Vallet S, Smith MR, Raje N (2010) Novel bone-targeted strategies in oncology.
Clin Cancer Res 16: 4084–4093.
3. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal
attraction. Nat Rev Cancer 11: 411–425.
4. Basak GW, Srivastava AS, Malhotra R, Carrier E (2009) Multiple myeloma
bone marrow niche. Curr Pharm Biotechnol 10: 345–346.
5. Yaccoby S (2010) Advances in the understanding of myeloma bone disease and
tumour growth. Br J Haematol 149: 311–321.
6. Fowler JA, Edwards CM, Croucher PI (2011) Tumor-host cell interactions in the
bone disease of myeloma. Bone 48: 121–128.
7. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, et al. (2007) Bone
marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia
21: 1079–1088.
8. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, et al. (2010) Distinct
transcriptional profiles characterize bone microenvironment mesenchymal cells
rather than osteoblasts in relationship with multiple myeloma bone disease. Exp
Hematol 38: 141–153.
9. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571,
imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug
Discov 1: 493–502.
10. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008)
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:
127–132.
11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, et al. (2008) Long-term
imatinib therapy promotes bone formation in CML patients. Blood 111:
2538–2547.
12. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC (2010)
Dysregulation of bone remodeling by imatinib mesylate. Blood 115: 766–774.
13. O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, et al. (2007) Imatinib
promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits
osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone
Miner Res 22: 1679–1689.
14. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, et al. (2006)
Imatinib as a potential antiresorptive therapy for bone disease. Blood 107:
4334–4337.
15. Olivieri A, Manzione L (2007) Dasatinib: a new step in molecular target therapy.
Ann Oncol 18 Suppl 6: vi42–46.
16. Aguilera DG, Tsimberidou AM (2009) Dasatinib in chronic myeloid leukemia: a
review. Ther Clin Risk Manag 5: 281–289.
17. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, et al. (2009)
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.
Leukemia 23: 994–997.
Bone Effects of Dasatinib
PLoS ONE | www.plosone.org 14 April 2012 | Volume 7 | Issue 4 | e3491418. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ (2009) Dasatinib
is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS
receptor. Leukemia 23: 590–594.
19. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, et al. (2010) Src family
kinase/abl inhibitor dasatinib suppresses proliferation and enhances differenti-
ation of osteoblasts. Oncogene 29: 3196–3207.
20. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, et al. (2010) The
Src inhibitor dasatinib accelerates the differentiation of human bone marrow-
derived mesenchymal stromal cells into osteoblasts. BMC Cancer 10: 298.
21. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, et al. (2011) Effects
of second-generation tyrosine kinase inhibitors towards osteogenic differentiation
of human mesenchymal cells of healthy donors. Hematol Oncol.
22. Jonsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, et al. (2010)
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem
cells and osteoblast differentiation in vitro. Leukemia 24: 1357–1359.
23. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, et al. (2003)
Development and functional characterization of human bone marrow
mesenchymal cells immortalized by enforced expression of telomerase.
Br J Haematol 120: 846–849.
24. Wang L, Zhao G, Olivares-Navarrete R, Bell BF, Wieland M, et al. (2006)
Integrin beta1 silencing in osteoblasts alters substrate-dependent responses to
1,25-dihydroxy vitamin D3. Biomaterials 27: 3716–3725.
25. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, et al. (2009)
Mesenchymal stem cells from multiple myeloma patients display distinct
genomic profile as compared with those from normal donors. Leukemia 23:
1515–1527.
26. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006)
Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement. Cytotherapy 8:
315–317.
27. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, et al. (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that
overcomes drug resistance. Cancer Res 66: 5781–5789.
28. Gregory CA, Gunn WG, Peister A, Prockop DJ (2004) An Alizarin red-based
assay of mineralization by adherent cells in culture: comparison with
cetylpyridinium chloride extraction. Anal Biochem 329: 77–84.
29. Xiao G, Jiang D, Ge C, Zhao Z, Lai Y, et al. (2005) Cooperative interactions
between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-
specific osteocalcin gene expression. J Biol Chem 280: 30689–30696.
30. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R (2004)
Human primary osteoclasts: in vitro generation and applications as pharmaco-
logical and clinical assay. J Transl Med 2: 6.
31. Chaudhary LR, Hofmeister AM, Hruska KA (2004) Differential growth factor
control of bone formation through osteoprogenitor differentiation. Bone 34:
402–411.
32. Hock JM, Canalis E (1994) Platelet-derived growth factor enhances bone cell
replication, but not differentiated function of osteoblasts. Endocrinology 134:
1423–1428.
33. Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C, et al. (2008) PDGF
receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone
Miner Res 23: 1519–1528.
34. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, et al. (2000) Decreased c-
Src expression enhances osteoblast differentiation and bone formation. J Cell
Biol 151: 311–320.
35. Veracini L, Franco M, Boureux A, Simon V, Roche S, et al. (2005) Two
functionally distinct pools of Src kinases for PDGF receptor signalling. Biochem
Soc Trans 33: 1313–1315.
36. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL
kinase inhibitors. Nat Biotechnol 25: 1035–1044.
37. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M (2005)
Mechanism of divergent growth factor effects in mesenchymal stem cell
differentiation. Science 308: 1472–1477.
38. Wang X, Goh CH, Li B (2007) p38 mitogen-activated protein kinase regulates
osteoblast differentiation through osterix. Endocrinology 148: 1629–1637.
39. Choi YH, Gu YM, Oh JW, Lee KY (2011) Osterix is regulated by Erk1/2
during osteoblast differentiation. Biochem Biophys Res Commun 415: 472–478.
40. Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, et al. (2007)
Gene expression profiling of human mesenchymal stem cells derived from bone
marrow during expansion and osteoblast differentiation. BMC Genomics 8: 70.
41. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell
127: 469–480.
42. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, et al. (2009) Bortezomib induces
osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF
signaling. Blood 113: 4319–4330.
43. Vaananen HK, Laitala-Leinonen T (2008) Osteoclast lineage and function.
Arch Biochem Biophys 473: 132–138.
44. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289: 1504–1508.
45. Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast
differentiation. Bone 40: 251–264.
46. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. (1994) c-
Fos: a key regulator of osteoclast-macrophage lineage determination and bone
remodeling. Science 266: 443–448.
47. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, et al. (1992)
Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741–745.
48. Takayanagi H (2007) The role of NFAT in osteoclast formation. Ann N Y Acad
Sci 1116: 227–237.
49. Martinez-Martinez S, Rodriguez A, Lopez-Maderuelo MD, Ortega-Perez I,
Vazquez J, et al. (2006) Blockade of NFAT activation by the second calcineurin
binding site. J Biol Chem 281: 6227–6235.
50. Nakamura I, Duong le T, Rodan SB, Rodan GA (2007) Involvement of
alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25: 337–344.
51. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, et al. (2001) Macrophage
inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is
independent of receptor activator of nuclear factor kappaB ligand. Blood 97:
3349–3353.
52. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, et al. (2003) Macrophage
inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling
cascades mediating survival and proliferation in multiple myeloma (MM) cells.
Blood 101: 3568–3573.
53. Roodman GD, Dougall WC (2008) RANK ligand as a therapeutic target for
bone metastases and multiple myeloma. Cancer Treat Rev 34: 92–101.
54. Charbord P (2010) Bone marrow mesenchymal stem cells: historical overview
and concepts. Hum Gene Ther 21: 1045–1056.
55. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999)
Multilineage potential of adult human mesenchymal stem cells. Science 284:
143–147.
56. Kagami H, Agata H, Tojo A (2011) Bone marrow stromal cells (bone marrow-
derived multipotent mesenchymal stromal cells) for bone tissue engineering:
basic science to clinical translation. Int J Biochem Cell Biol 43: 286–289.
57. Khosla S, Westendorf JJ, Modder UI (2010) Concise review: Insights from
normal bone remodeling and stem cell-based therapies for bone repair. Stem
Cells 28: 2124–2128.
58. Nandi SK, Roy S, Mukherjee P, Kundu B, De DK, et al. (2010) Orthopaedic
applications of bone graft & graft substitutes: a review. Indian J Med Res 132:
15–30.
59. Mazo M, Gavira JJ, Abizanda G, Moreno C, Ecay M, et al. (2010)
Transplantation of mesenchymal stem cells exerts a greater long-term effect
than bone marrow mononuclear cells in a chronic myocardial infarction model
in rat. Cell Transplant 19: 313–328.
60. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, et al. (2006) Dasatinib
(BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal
models predict optimal clinical exposure. Clin Cancer Res 12: 7180–7186.
61. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, et al. (2010) The
tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through
inhibition of osteoclasts in vivo. J Bone Miner Res 25: 1759–1770.
62. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, et al. (2008) Metabolism
and disposition of dasatinib after oral administration to humans. Drug Metab
Dispos 36: 1357–1364.
63. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367: 2010–2018.
64. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, et al. (2007)
Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer
97: 964–970.
65. Roodman GD (2009) Pathogenesis of myeloma bone disease. Leukemia 23:
435–441.
66. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, et al. (2007)
Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk
Lymphoma 48: 2032–2041.
67. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM
(2001) Abnormalities of bone marrow mesenchymal cells in multiple myeloma
patients. Cancer 91: 1219–1230.
68. Yaccoby S (2010) Osteoblastogenesis and tumor growth in myeloma. Leuk
Lymphoma 51: 213–220.
69. Giuliani N, Rizzoli V, Roodman GD (2006) Multiple myeloma bone disease:
Pathophysiology of osteoblast inhibition. Blood 108: 3992–3996.
70. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, et al. (2008)
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in
patients with multiple myeloma: preclinical efficacy of the novel, orally available
inhibitor dasatinib. Blood 112: 1346–1356.
71. Rosen LS (2004) New generation of bisphosphonates: broad clinical utility in
breast and prostate cancer. Oncology (Williston Park) 18: 26–32.
72. Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, et al. (2009)
The use of bisphosphonates in multiple myeloma: recommendations of an expert
panel on behalf of the European Myeloma Network. Ann Oncol 20: 1303–1317.
Bone Effects of Dasatinib
PLoS ONE | www.plosone.org 15 April 2012 | Volume 7 | Issue 4 | e34914